Do you care for patients with “diabesity” (type 2 diabetes and obesity) and want to better understand how incretin hormone targeting medications like GLP-1 receptor agonists have revolutionized the treatment of these conditions? Are you interested in the emerging data around incretin multiagonists and how they may further extend the benefits of GLP-1 receptor agonists provide in this patient population?

If so, take part in this self-paced curriculum that reviews the physiology behind incretin-based agonists and discusses their current and rapidly expanding role in the care of people with type 2 diabetes and obesity. There are 4 activities in total, including one 60-minute session overview of all the learning objectives, in addition to a 3-part series of short interactive video modules that are broken down by topic and go into more detail on each learning objective. Earn a maximum of 2.5 AMA credits by completing all 4 activities!

Learning Objectives

  • Discuss the interrelationship between T2DM and obesity and the therapeutic advantages of early treatment intensification to reduce the long-term health risks associated with both conditions.
  • Explore incretin physiology to understand the clinical benefits of incretin-based therapies on glycemic control, weight, and other metabolic processes.
  • Evaluate clinical trial evidence that demonstrates the value of incretin-based multireceptor agonism in the future care of patients with T2DM, obesity, and related metabolic disorders.


Jennifer B. Green, MD

Professor of Medicine
Department of Medicine, Division of Endocrinology
Faculty Member, Duke Clinical Research Institute
Duke University Medical Center
Durham, NC

Robert F. Kushner, MD, FACP

Professor, Departments of Medicine and Medical Education
Northwestern University Feinberg School of Medicine
Chicago, IL

Commercial Supporters

Lilly. For further information concerning Lilly grant funding visit

Education Partners

Pri-Med Institute

Fine Print

The preferred browser is Google Chrome. If using a different browser, such as Safari, Firefox or Edge, make sure you are using the most up-to-date version. Your Internet settings should be set to accept cookies and JavaScript. If cookies and/or JavaScript are disabled, the site may not function properly. A high-speed Internet connection is not required; however, it is recommended for faster download times.

The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed, nor do they necessarily reflect, those of their affiliated institutions, Pri-Med Institute, Pri-Med Institute Advisory Boards and Consultants, or DBC Pri-Med, LLC.

Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients.

Pri-Med Institute Accredited Provider
Pri-Med programs are owned and operated by DBC Pri-Med, LLC, a division of Diversified Communications, Inc. Pri-Med Institute, the accredited division of Pri-Med, is accredited with commendation by the ACCME and approved as a provider of continuing education by the AANP. Pri-Med Institute is the accredited provider for this activity.

Disclosures and Conflict of Interest
Pri-Med Institute requires all individuals in a position to influence educational content for Pri-Med Institute-certified CME activities to disclose relevant personal financial relationships with commercial interests prior to contributing to its educational activities. Pri-Med Institute assesses disclosed relationships and follows a defined process to resolve real or implied conflicts to ensure, to the best of its ability, that all educational content is free of commercial bias. Financial disclosures are listed in the activity syllabus and will also be printed on the slides and announced at the start of each presentation. Pri-Med Institute and Vindico Medical Education staff have no relevant financial relationships to disclose.

Discussion of Off-Label Uses and Investigational Products
During the course of their presentations, the faculty may mention uses of products that have not been approved in the United States for the indication(s) being discussed. All presenters are instructed to notify participants when they are discussing unapproved uses or investigational agents. In addition, specific slides will include notation of the off-label use or investigational agent being discussed. Views presented related to unapproved uses of products are solely those of the presenter(s) and are not endorsed by Pri-Med Institute or DBC Pri-Med, LLC.

Questions? If you have questions about this activity, please email or call (877) 477-4633.

Pri-Med Institute educational activities are developed and conducted in accordance with the ACCME's Essential Areas and Policies. It is the mission of Pri-Med Institute to develop and present educational activities that are timely, fair-balanced, scientifically rigorous, and that serve to improve patient outcomes. To that end, we welcome your comments about how to better serve your needs.